KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Q2 2025 value amounting to $844.2 million.

  • Jazz Pharmaceuticals' Capital Expenditures rose 1180483.71% to $844.2 million in Q2 2025 from the same period last year, while for Sep 2025 it was $871.3 million, marking a year-over-year increase of 239774.97%. This contributed to the annual value of $38.1 million for FY2024, which is 5887.66% up from last year.
  • Per Jazz Pharmaceuticals' latest filing, its Capital Expenditures stood at $844.2 million for Q2 2025, which was up 1180483.71% from $13.9 million recorded in Q1 2025.
  • Jazz Pharmaceuticals' Capital Expenditures' 5-year high stood at $844.2 million during Q2 2025, with a 5-year trough of -$4.9 million in Q3 2022.
  • For the 5-year period, Jazz Pharmaceuticals' Capital Expenditures averaged around $54.3 million, with its median value being $8.9 million (2021).
  • Its Capital Expenditures has fluctuated over the past 5 years, first crashed by 15886.17% in 2022, then soared by 1180483.71% in 2025.
  • Over the past 5 years, Jazz Pharmaceuticals' Capital Expenditures (Quarter) stood at $10.0 million in 2021, then dropped by 5.91% to $9.4 million in 2022, then increased by 7.72% to $10.1 million in 2023, then surged by 31.53% to $13.3 million in 2024, then skyrocketed by 6253.37% to $844.2 million in 2025.
  • Its Capital Expenditures was $844.2 million in Q2 2025, compared to $13.9 million in Q1 2025 and $13.3 million in Q4 2024.